Iloprost is a prostacyclin receptor agonist that promotes vasodilation of circulatory beds with minimal impact on hemodynamic parameters. It is licensed for the treatment of pulmonary arterial hypertension and is widely used for the management of peripheral vascular disease and digital vasculopathy, including digital ulcers and critical digital ischemia in systemic sclerosis. There is a case series of three morbidly obese patients with severe COVID-19 and systemic microvasculopathy who obviously benefitted from its use (Moezinia 2020).
Find the entire treatment chapter at https://covidreference.com/treatment
Acalabrutinib – Anticomplement therapies – Azithromycin – Camostat – Chloroquine – Colchicine – Convalescent plasma – Corticosteroids – Cytokine blockers – Famotidine – Favipiravir – G-CSF – Human recombinant soluble ACE2 – Hydroxychloroquine – Ibrutinib – Iloprost – Interferons – JAK inhibitors – Leflunomide – Lopinavir – Monoclonal antibodies – N-acetylcysteine – Oseltamivir – (other) Protease inhibitors – (other) RdRp inhibitors – REGN-COV2 – Umifenovir